Shares of Advaxis, Inc. (NASDAQ:ADXS) dropped 5.7% on Tuesday . The stock traded as low as $0.69 and last traded at $0.72. Approximately 919,127 shares traded hands during trading, an increase of 4% from the average daily volume of 880,848 shares. The stock had previously closed at $0.76.
Separately, HC Wainwright restated a “buy” rating on shares of Advaxis in a research report on Wednesday, September 12th.
The stock has a market capitalization of $49.66 million, a price-to-earnings ratio of -0.31 and a beta of 1.82.
In other news, Director Roni Appel bought 33,333 shares of the stock in a transaction on Tuesday, September 11th. The stock was acquired at an average price of $1.20 per share, with a total value of $39,999.60. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 4.72% of the stock is owned by corporate insiders.
A number of institutional investors and hedge funds have recently modified their holdings of the business. BlackRock Inc. increased its holdings in Advaxis by 28.2% in the 1st quarter. BlackRock Inc. now owns 2,925,417 shares of the biotechnology company’s stock worth $4,943,000 after purchasing an additional 644,201 shares in the last quarter. Paloma Partners Management Co acquired a new position in Advaxis in the 2nd quarter worth about $265,000. Franklin Street Advisors Inc. NC acquired a new position in Advaxis in the 2nd quarter worth about $190,000. Finally, LMR Partners LLP acquired a new position in Advaxis in the 2nd quarter worth about $171,000. 21.50% of the stock is owned by institutional investors and hedge funds.
Advaxis Company Profile (NASDAQ:ADXS)
Advaxis, Inc, a clinical stage biotechnology company, focuses on the discovery, development, and commercialization of Listeria monocytogenes (Lm) technology based immunotherapies in the United States. It is developing Axalimogene filolisbac and ADXS-Dual that are Lm-LLO immunotherapy product candidates for the treatment of human papilloma virus associated cancers, including cervical, and head and neck cancers.
Read More: Do You Need a Fiduciary?
Receive News & Ratings for Advaxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis and related companies with MarketBeat.com's FREE daily email newsletter.